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Mesangial accumulation of GA-pyridine, a novel
glycolaldehyde-derived AGE, in human renal disease.
Background. Advanced glycation end products (AGEs) con-
tribute to diabetic and atherosclerotic end-organ damage, but
the mechanisms of AGE-formation and AGE-induced dam-
age are unclear. Glycolaldehyde (GA) is a Maillard-reaction
intermediate and can be formed by reaction of L-serine with
the myeloperoxidase-system. GA reacts with proteins to form
AGEs, such as GA-pyridine, which is specific for protein
modification by GA. GA-pyridine accumulates in human
atherosclerotic lesions. As atherosclerosis and progressive
glomerulosclerosis share many similarities, we hypothesized
that GA-pyridine accumulates in renal diseases, especially those
with prominent mesangial involvement.
Methods. Paraffin-embedded renal biopsies from 55 patients
with various renal diseases, as well as control tissue, obtained
from the unaffected part of kidneys from 10 patients with re-
nal cell carcinoma were immunohistochemically stained with a
monoclonal antibody directed against GA-pyridine and were
scored semiquantitatively. Additional sections were scored for
mesangial matrix expansion (MME) and focal glomerular scle-
rosis (FGS).
Results. In normal human kidneys, GA-pyridine was mainly
localized in tubular epithelial cells, but not in the glomerular
mesangium. Significant mesangial GA-pyridine accumulation
was found in disorders with mesangial involvement as a com-
mon denominator. In contrast, mesangial GA-pyridine accumu-
lation was less prominent in renal diseases without prominent
mesangial involvement. Moreover, mesangial GA-pyridine ac-
cumulation was more pronounced in kidneys with higher MME
and FGS scores across the different diagnoses.
Conclusion. GA-pyridine accumulates in the mesangium in
human renal disease, in particular in disorders with mesangial
involvement. Further studies should elucidate whether mesan-
gial GA-pyridine plays a role in the progression of glomerular
damage.
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Advanced glycation end products (AGEs), formed in
the Maillard reaction, accumulate with normal aging [1],
but accelerated AGE formation is seen in diabetes [2]
and uremia [3]. In normal physiologic conditions, AGEs
are cleared by the kidney, implicating that deterioration
in renal function results in AGE accumulation [4, 5]. Fur-
thermore, the AGE inhibitor pyridoxamine diminishes
end-organ damage of the kidney [6, 7], supporting its
pathophysiologic significance.
There are at least 2 mechanisms by which AGEs may
contribute to tissue injury. First, AGE modification di-
rectly alters the structure and function of extracellular
matrix proteins [4, 8]. Second, AGEs modulate cellular
functions through ligation of specific cell surface recep-
tors, such as RAGE [9], SR-A (scavenger receptor A)
[10], CD36 [11], and LOX-1 [12]. By binding to these
receptors, AGEs could give rise to altered gene expres-
sion [9], tubular epithelial mesenchymal transformation
(TEMT) [13], monocyte migration [14], cellular oxidative
stress, increased vascular permeability, and up-regulation
of cell adhesion molecules [8, 15].
Many different AGEs, formed in various pathways,
have been identified so far [4]. Glycolaldehyde formed
either as a fragmentation product in the Maillard reac-
tion [16] or as a result of the myeloperoxidase-hydrogen
peroxide-chloride (MPO) reaction [17] can react with
proteins to yield various AGEs. Recently, a novel spe-
cific GA-derived AGE, called GA-pyridine, has been
described in foam cells and in the extracellular matrix
of human atherosclerotic fibrotic lesions [18]. The pres-
ence of GA-pyridine in atherosclerotic lesions suggests
an active participation of this AGE in the initiation and
progression of atherosclerosis [18].
Progressive glomerulosclerosis shares many similar-
ities with atherosclerosis, including enhanced extra-
cellular mesangial matrix deposition and macrophage
infiltration [19]. However, until now no data have been
available on GA-pyridine in the human kidney, so it
is unknown whether GA-pyridine accumulates in re-
nal disorders as well. Therefore, to elucidate a possible
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contributing role of GA-pyridine in the pathogenesis
of renal diseases, in particular those with prominent
mesangial involvement, we studied the accumulation of
GA-pyridine in various renal disorders and in control
renal tissue. Moreover, we studied whether mesangial
GA-pyridine deposition was related to the extent of
glomerular damage assessed as mesangial matrix expan-
sion (MME) and focal glomerular sclerosis (FGS). Fi-
nally, to reveal possible involvement of the MPO-system
in the formation of renal GA-pyridine in human renal
diseases, we studied the colocalization of GA-pyridine
and MPO.
METHODS
Patients
Renal biopsies from 55 patients with various renal
diseases who were admitted and examined in the Uni-
versity Medical Center Groningen served as the study
group. Morphologic diagnoses were made by a quali-
fied pathologist, unrelated to the present study. Patients
were selected to represent a variety of disorders with
prominent mesangial involvement (N = 32) [diabetic
nephropathy (N = 10), Wegener’s granulomatosis (N =
8), mesangial proliferative glomerulonephritis (N = 7),
focal glomerulosclerosis (N = 7)], as well as disor-
ders without prominent mesangial involvement (N =
23) [membranous glomerulonephritis (N = 7), minimal
change disease (N = 8), and chronic allograft rejection
(N = 8)]. Control renal tissue (N = 10) was obtained
from the unaffected part of kidneys from patients under-
going surgery for renal cell carcinoma. Tissue was fixed in
4% paraformaldehyde and processed for paraffin embed-
ding according to standard procedures. Clinical parame-
ters (blood pressure, serum creatinine, and proteinuria),
obtained at the time of biopsy were determined for all
different groups.
Assessment of renal morphologic damage
Renal biopsies, routinely stained with hematoxylin
and eosin, methanamine-silver, or periodic acid–Schiff
(PAS), were blindly scored by a qualified pathologist for
glomerular MME and FGS. MME was scored positive if
the broadening of the mesangial areas was 2 to 3 times
that of the mesangial width seen in control glomeruli.
FGS was scored positive when collapse of capillary lu-
mens, mesangial matrix expansion, hyalinosis, and adhe-
sion formation were simultaneously present. Glomeruli
were scored for MME and FGS as follows: unaffected
glomeruli were scored as 0, if 1 quadrant was affected
with MME or FGS a score of 1 was adjusted, 2 quad-
rants affected was scored as 2, 3 quadrants as 3, and if
all quadrants were positive for MME or FGS, a score of
4 was given. The means for MME or FGS of all scored
glomeruli of 1 biopsy were calculated.
Immunohistochemistry
Paraffin sections (4 lm) were dewaxed, rehydrated,
and endogenous peroxidase was blocked with 0.3%
H2O2 in phosphate-buffered saline (PBS) for 30 minutes.
Sections were incubated with a mouse monoclonal anti-
GA-pyridine antibody (0.5 lg/mL) [18] for 60 minutes.
Antibody dilutions were made in PBS, and supplemented
with 1% normal human serum. The specificity of this
antibody has been confirmed previously by noncompeti-
tive enzyme-linked immunosorbent assay (ELISA) [18].
Binding of the antibody was detected using sequential
incubations with peroxidase (PO)-labeled rabbit anti-
mouse and PO-labeled goat antirabbit antibodies; both
for 30 minutes. Peroxidase activity was developed by us-
ing 3,3′-diaminobenzidine tetrachloride for 10 minutes.
Sections were counterstained with hematoxylin.
Three types of control tests were performed to deter-
mine the specificity of the antibody in tissue sections.
First, control sections were incubated with anti-GA-
pyridine antibody solutions, after being preincubated
with the antigen to which it is directed i.e. GA-BSA [18].
Second, sections were incubated with unrelated mouse
monoclonal antibody (antirat macrophages, ED-1), and
third, sections were incubated with PBS, both in absence
of primary antibodies.
Immunohistochemical staining intensity in glomeruli
and interstitium was assessed by semiquantitative scoring
on a scale of 0 to +++, 0 (absent), ± (occasionally weak),
+ (weak), ++ (moderate), +++ (strong staining). Data
were converted to percentages [8], moderate to strong
staining (++ to +++), and any positive staining (± to
+++) (Tables 2 and 3, respectively).
To determine any colocalization of GA-pyridine with
MPO, consecutive sections were stained for MPO
(a-MPO, 1:4800; Dako, Glosstrup, Denmark) and GA-
pyridine, using the same protocol as above. Binding of the
MPO antibody, however, was detected using a single in-
cubation with peroxidase (PO)-labeled rabbit antimouse.
Statistics
One-way analysis of variance (ANOVA) was used to
detect differences in clinical parameters, and Kruskal-
Wallis was used to detect differences in pathologic pa-
rameters between the patient groups.
To test for the effect of age on mesangial GA-pyridine
accumulation in diseases with prominent mesangial in-
volvement, the study subjects were grouped by a break-
up according to age being above or below the median
value of the group. Mann-Whitney test was used for com-
parison between the 2 age groups.
To detect associations between MME or FGS and GA-
pyridine accumulation, MME and FGS were split into
quartiles, the first quartile representing the biopsies with
the lowest MME and FGS scores and the fourth quartile
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Table 1. Clinical and pathologic data
Serum Mesangial Focal
M/F Age SBP DBP creatinine Proteinuria matrix glomerular
N year mm Hg mm Hg lg/L g/day expansion sclerosis
Control 5/5 66 (29–73) 135 (105–180) 75 (65–80) 104 (73–156) – 0.06 (0.0–0.21) 0.0 (0.0–0.0)
Diabetic nephropathy 4/6 51 (42–70) 170 (120–185) 92 (50–105) 119 (89–406) 3.8 (0.1–10) 3.61 (1.92–4.0) 1.61 (0.33–3.33)
Wegener’s granulomatosis 5/3 71 (55–81) 118 (100–130) 63 (60–95) 389 (110–550) 0.5 (0.3–6.1) 1.47 (0.20–2.71) 0.91 (0.0–2.47)
Mesangial proliferative 6/1 45 (34–83) 134 (110–170) 80 (75–86) 141 (121–264) 2.8 (1.0–6.3) 2.26 (0.30–3.08) 0.36 (0.09–2.0)
glomerulonephritis
Focal glomerular sclerosis 6/1 51 (23–80) 148 (115–180) 80 (60–110) 273 (76–896) 6.4 (1.8–11.6) 2.83 (1.25–3.39) 2.50 (0.25–3.32)
Membranous 5/2 51 (33–69) 120 (100–164) 80 (70–82) 137 (69–339) 5.1 (3.1–13.8) 2.15 (0.46–3.33) 1.02 (0.0–3.0)
glomerulonephritis
Minimal change 7/1 7 (2–14) 124 (94–160) 70 (50–80) 37 (33–68) 2.65 (0–8.9) 0.46 (0.0–2.44) 0.0 (0.0–0.89)
Allograft rejection 4/4 59 (40–67) 145 (105–170) 80 (70–90) 207 (149–473) 0.2 (0.1–0.2) 0.42 (0.18–0.83) 0.0 (0.0–0.42)
Abbreviations are: M/F, male-to-female ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. Values are expressed as median and range.
Table 2. Percentage of moderate to strong GA-pyridine staining in control and human renal disease
GA-pyridine staining
Glomerulus Interstitium
Epithelium Vessels
Tubular Peritubular
Mesangium Endothelium Visceral Parietal epithelium capillaries SMC Endothelium
Control 0 0 30 20 100 0 50 30
Diabetic nephropathy 50 0 30 50 100 0 20 30
Wegener granulomatosis 38 0 38 38 100 0 50 17
Mesangial proliferative glomerulonephritis 43 0 14 57 100 0 14 14
Focal glomerular sclerosis 28 0 14 14 100 0 50 17
Membranous glomerulonephritis 0 14 0 0 100 0 14 14
Minimal change 0 13 0 0 100 0 13 0
Allograft rejection 0 0 0 0 100 0 33 0
Abbreviations are: SMC, smooth muscle cells.
representing the highest scores. Kruskal-Wallis test was
used for comparison between the quartiles.
RESULTS
Patient characteristics
Patient characteristics are presented in Table 1. No
significant differences in age were present between the
groups, including controls, except for the patients with
minimal change disease, who were significantly younger.
Blood pressure and plasma creatinine were not signif-
icantly different between the groups. Proteinuria (not
measured in controls) did differ between the groups
(Table 1). As expected, MME and FGS scores were dif-
ferent between the different diagnostic categories (P <
0.001).
GA-pyridine in the normal human kidney
Strong staining of GA-pyridine was seen in proximal
and distal tubular epithelial cells (Table 2, Fig. 1A). Also,
strong GA-pyridine staining was found in the endothe-
lium and smooth muscle cells of renal vessels and in the
visceral and parietal glomerular epithelium (Table 2). In
only 1 patient weak GA-pyridine staining was noted in
the peritubular capillaries and the glomerular mesangium
(Table 3). No staining was present in the glomerular en-
dothelium in any of the control sections (Table 3).
GA-pyridine in renal diseases with prominent mesangial
involvement
Strong glomerular mesangial GA-pyridine accumula-
tion was present in patients with diabetic nephropathy
(Table 2, Fig. 1C). Mesangial staining was not just lim-
ited to areas with expanded mesangium but was also
present in the nonexpanded mesangium. The classical
noduli, known as Kimmelstiel-Wilson lesions, were oc-
casionally encountered: these were negative for GA-
pyridine (Fig. 1D). In addition, glomerular mesangial
GA-pyridine accumulation was also prominent in
Wegener’s granulomatosis (Fig. 1B), mesangial prolifer-
ative glomerulonephritis (Fig. 1E), and focal glomerular
sclerosis. Weak staining of GA-pyridine was observed in
the glomerular endothelium and the peritubular capil-
laries in these diseases (Table 3). Strong GA-pyridine
staining was observed in tubular epithelial cells (Table 2),
in the renal vasculature, and in the visceral and pari-
etal glomerular epithelium (Table 2), which was similar
to the staining in normal kidneys. GA-pyridine staining
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Fig. 1. Staining of GA-pyridine. (A) Rep-
resentative photograph of a section from a
control kidney. GA-pyridine is abundantly
present in cortical tubular segments (arrow).
No glomerular mesangial staining is present.
(B) Example of a section from a renal biopsy
from a patient with Wegener’s granulomato-
sis. In addition to tubular staining, abundant
accumulation of GA-pyridine is found in the
glomerular mesangium (arrow). (C) Photo-
graph of a section from a diabetic kidney. In
addition to the tubular staining, abundant ac-
cumulation of GA-pyridine is found in the
glomerular mesangium (arrow). (D) Photo-
graph of a section from a diabetic kidney, with
a Kimmelstiel-Wilson nodulus (arrow). Al-
though no GA-pyridine accumulation is seen
within the nodulus, staining is obvious in the
outer layers. (E) Example of a section from a
patient with mesangial proliferative glomeru-
lonephritis. In addition to tubular staining,
abundant accumulation of GA-pyridine is
found in the glomerular mesangium (arrow).
(F) Photograph of a section from a patient
with chronic renal allograft rejection. Strong
GA-pyridine staining is seen in the tubular
cells (arrow), whereas, in contrast to B, C, and
E, no glomerular GA-pyridine staining is seen
in this biopsy.
Table 3. Percentage of any positive GA-pyridine staining in control and human renal disease
GA-pyridine staining
Glomerulus Interstitium
Epithelium Vessels
Tubular Peritubular
Mesangium Endothelium Visceral Parietal epithelium capillaries SMC Endothelium
Control 10 0 60 80 100 10 100 80
Diabetic nephropathy 100 100 100 100 100 90 90 100
Wegener’s granulomatosis 75 100 88 88 100 100 100 100
Mesangial proliferative glomerulonephritis 71 100 71 100 100 57 100 86
Focal glomerular sclerosis 86 86 71 100 100 71 100 100
Membranous glomerulonephritis 57 100 86 71 100 71 100 100
Minimal change 38 75 38 75 100 75 100 100
Allograft rejection 13 100 57 75 100 63 100 100
Abbreviations are: SMC, smooth muscle cells.
of older patients (age > median) was compared to GA-
pyridine staining in younger patients (age < median).
GA-pyridine staining was significantly more pronounced
in the mesangium of older patients (N = 14, median 69,
range 55–83) than in younger patients (N = 14, median
44, range 23–51) (P = 0.05). GA-pyridine staining was not
significantly associated with the indices for the severity of
renal damage, such as creatinine and proteinuria.
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Fig. 2. Control sections. (A) Photograph of a section from a patient with diabetic nephropathy, stained with anti-GA-pyridine antibody solutions,
preincubated with GA-BSA. No staining at all is present. (B) Photograph of a section from a patient with diabetic nephropathy, incubated with an
irrelevant mouse monoclonal antibody as a negative control. Also, no GA-pyridine staining is present.
Fig. 4. Colocalization studies for GA-pyridine with MPO. (A) Photograph of a section from a patient with Wegener’s granulomatosis. Multiple
MPO-positive cells (arrow) are present in the glomerulus. (B) Photograph of the same glomerulus (stained in serial sections), stained for GA-
pyridine. Note the difference in staining pattern when compared to MPO staining (A).
GA-pyridine in diseases without prominent
mesangial involvement
Weak GA-pyridine accumulation was observed in
the glomerular mesangium and endothelium in patients
with membranous glomerulonephritis, minimal change
nephropathy, and renal allograft rejection (Table 3,
Fig. 1F). Again, strong GA-pyridine staining was ob-
served in tubular epithelial cells (Table 2), which was
similar to the staining in normal kidneys. In addition,
GA-pyridine was present in the renal vasculature and in
the visceral and parietal glomerular epithelium (Table 3).
Glomerular mesangial GA-pyridine staining (which was
similarly weak in this group) showed no significant differ-
ences between biopsies from older or younger patients.
Control sections
Control sections, incubated with anti-GA-pyridine an-
tibody solutions that were preincubated with GA-BSA
(Fig. 2A), sections incubated with irrelevant mouse mon-
oclonal antibodies instead of anti-GA-pyridine antibody
(Fig. 2B), and sections incubated with only PBS were con-
sistently negative.
Association between glomerular pathology and
mesangial GA-pyridine
The association between mesangial GA-pyridine stain-
ing and glomerular pathology, estimated as MME and
FGS, is given in Figure 3, providing a semiquantitative
assessment of GA-pyridine staining per quartile of MME
and FGS, respectively. This shows that enhanced mesan-
gial GA-pyridine accumulation is associated with increas-
ing MME and FGS (Kruskal-Wallis, P = 0.001).
Colocalization studies with MPO
Using an anti-MPO antibody, we found MPO-positive
cells in the glomeruli and in the interstitium in a va-
riety of renal diseases. Consecutive sections, however,
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Fig. 3. Mesangial GA-pyridine staining (mean and standard deviation) by a break-up in quartiles of MME (A) and FGS (B). (A) A significant
difference in GA-pyridine staining was present between the quartiles of MME (Kruskal-Wallis, P = 0.001). (B) A significant difference in GA-
pyridine staining was present between the quartiles of FGS (Kruskal-Wallis, P = 0.001).
revealed no colocalization of these cells (Fig. 4A) with
GA-pyridine (Fig. 4B) (photographs shown are from a
patient with Wegener’s granulomatosis).
DISCUSSION
The present study describes for the first time the
distribution of a novel AGE, GA-pyridine in the nor-
mal human kidney and in human renal diseases. Most
importantly, we showed significant accumulation of
GA-pyridine in the glomerular mesangium in renal dis-
eases, in particular those with prominent mesangial in-
volvement. This mesangial accumulation was related to
the degree of glomerular MME and FGS. In addition,
GA-pyridine was found in tubular epithelia and in the
renal vasculature: this staining was present in both nor-
mal and diseased kidneys, and appears, therefore, not to
be related to renal pathology.
Under physiologic conditions, circulating AGEs are
cleared by the kidney by glomerular filtration, and are
subsequently actively reabsorbed and metabolized by
proximal tubular cells [20, 21] GA-pyridine was abun-
dantly and consistently present in cortical tubular cells
from normal and diseased human kidneys in our study.
This is in concordance with data on other AGEs and
advanced lipoxygenation end products (ALEs), such as
pentosidine and MDA-lysine, which are also present
in proximal tubular cells from normal renal tissue, as
well as tissue from patients with diabetic nephropathy
and mesangial proliferative glomerulonephritis [22]. The
tubular accumulation of GA-pyridine in normal and dis-
eased human kidneys, therefore, may reflect the normal
tubular uptake of this AGE from the plasma, as GA-
modified proteins have been shown to be present in hu-
man serum [23].
Based on the parallel between atherosclerosis, where
GA-pyridine accumulation was previously described
[18], and glomerulosclerosis [19], we expected to find
GA-pyridine accumulation in the glomerular mesangium
of renal diseases with prominent mesangial involvement.
This would be in concordance with previous reports de-
scribing the accumulation of AGEs such as CML, pento-
sidine, and pyrraline in the expanded mesangial areas of
patients with diabetic nephropathy and IgA nephropa-
thy (mesangial proliferative glomerulonephritis) [24,
25]. Furthermore, AGEs have been described in the
mesangium of aging rat [26, 27]. Significant GA-pyridine
accumulation was indeed found in diabetic nephropa-
thy, Wegener’s granulomatosis, mesangial proliferative
glomerulonephritis, and focal glomerulosclerosis. Renal
disorders without significant glomerular mesangial in-
volvement, such as renal transplantation, membranous
glomerulonephritis, and minimal change nephropathy
only revealed minor mesangial GA-pyridine accumu-
lation. Moreover, mesangial GA-pyridine accumulation
appeared to be related to higher scores for MME and FGS
across the different disorders. This suggests that mesan-
gial GA-pyridine accumulation is more closely related to
the severity of glomerular mesangial pathology, as such,
than to the classifying diagnosis.
In our patients with renal diseases with mesangial in-
volvement, GA-pyridine localization was not only limited
to areas with mesangial matrix expansion, but was also
present in areas with morphologically intact mesangium.
This is compatible with the assumption that GA-pyridine
accumulation is not merely an epiphenomenon to dam-
age, but can precede mesangial expansion and may, thus,
play a role in the pathogenesis of these lesions. Studies
demonstrating protection against diabetic renal damage
by intervention in AGE formation by pyridoxamine [6, 7]
and, specifically, reduction of mesangial matrix expansion
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by aminoguanidine [28], support the pathogenetic rele-
vance of AGEs for renal damage. The mechanisms of the
pathogenetic role of AGEs in renal damage have been
subject of many studies. It has been found that nonenzy-
matic glycation (i.e., by glycolaldehyde) could influence
the growth of mesangial cells, which could contribute to
the mesangial abnormalities of diabetic glomerulopathy
[29]. Also, AGE-modified proteins have been demon-
strated to up-regulate mesangial growth factor [30], and
to stimulate synthesis of fibronectin and type IV colla-
gen by glomerular mesangial cells [31]. AGEs could give
rise to cellular responses through binding to receptors,
and recent data show that, among the different receptors
for cellular AGE uptake, at least 3 of them, RAGE [32],
SR-A [10], and CD36 [33] not only recognize glucose-
modified protein but also GA-modified proteins.
In diabetic nephropathy nodular mesangial le-
sions, known as intercapillary glomerulosclerosis or
Kimmelstiel-Wilson lesions, are sometimes present. Al-
though these lesions are essentially similar to the dif-
fuse mesangial lesions, we did not detect GA-pyridine
staining in those lesions. However, the outer layers were
positively stained for GA-pyridine. Strong nodular im-
munostaining by anti-pentosidine and anti-AGE poly-
clonal antibodies has been described [25]. In contrast,
Uesugi et al noted the absence of CML in some nodu-
lar lesions [24]. These results indicate that the pattern
of distribution may vary between various AGEs. Also,
differences in staining methods cannot be excluded.
The renal vasculature was of special interest, consider-
ing the accumulation of GA-pyridine in atherosclerotic
lesions [18]. We found GA-pyridine in the renal vessels
of both patients and controls, despite the absence of foam
cells. GA-pyridine staining was present in the endothe-
lium and in the smooth muscle cells, and in the cells of the
thickened intima (mainly fibroblasts) in normal as well as
diseased kidneys. These data are in concordance with the
literature, reporting accumulation of pentosidine, CML,
and pyrraline in thickened intima of renal arteries in DN
[25]. Unlike mesangial GA-pyridine, GA-pyridine in the
renal vasculature was present in both normal and dis-
eased kidneys and seems, therefore, not to be related to
renal pathology. This was also the case for tubular GA-
pyridine accumulation.
In our renal patients, accumulation of GA-pyridine was
slightly increased in the glomerular endothelium com-
pared to control kidneys. This is in accordance with pre-
vious studies showing AGEs in glomerular endothelial
cells in diabetic rat [34]. It is also known that CML and
CEL plasma levels are associated with markers of en-
dothelial activation [35]. Moreover, AGEs are known to
induce increased permeability and enhance endothelium-
dependent procoagulant activity through endothelial cell
AGE-receptors in cultured endothelial cells [36]. So a
possible pathogenetic role of GA-pyridine in renal dam-
age might involve effects on the endothelium of renal
vessels and glomerulus.
In our study, a higher age was associated with more
GA-pyridine accumulation in the diseases with promi-
nent mesangial involvement, but not in the other patient
groups or in controls. This suggests that mesangial pathol-
ogy may act as a permissive factor in age-related accumu-
lation of GA-pyridine and vice versa.
One of the factors involved in the formation of GA-
pyridine is the MPO system [18]. To reveal its possible
role in GA-pyridine formation in renal diseases, we per-
formed MPO staining and GA-pyridine staining in con-
secutive sections. However, MPO did not colocalize with
GA-pyridine in the renal disorders studied here. In fact,
most GA-pyridine was found in DN, in which MPO activ-
ity is known to be decreased [37]. Our results suggest that,
in the renal conditions studied here, the MPO system is
not crucially involved in the formation of GA-pyridine.
This indicates that other mechanisms, such as the
Maillard reaction, could be more important in its forma-
tion in renal disease.
CONCLUSION
The newly discovered AGE, GA-pyridine, is present
in diseased kidneys, especially those with prominent
mesangial involvement. Moreover, its accumulation in
the mesangium is related to the severity of MME and
FGS. Further studies, aimed at intervention in the forma-
tion of GA-pyridine, or preventing its binding to specific
receptors, may provide new therapeutic strategies and
shed new light on its possible role in the pathogenesis of
renal lesions.
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